Execution du pipeline. Actualisation des dois et des graphes.

1-enrich-with-datacite/all_datacite_clients_for_uga.csv

 client,count,name,year,url
-cern.zenodo,981,Zenodo,2013,https://zenodo.org/
+cern.zenodo,982,Zenodo,2013,https://zenodo.org/
 inist.sshade,468,Solid Spectroscopy Hosting Architecture of Databases and Expertise,2019,https://www.sshade.eu/
 inist.osug,238,Observatoire des Sciences de l'Univers de Grenoble,2014,http://doi.osug.fr
-figshare.ars,213,figshare Academic Research System,2016,http://figshare.com/
+figshare.ars,219,figshare Academic Research System,2016,http://figshare.com/
 dryad.dryad,157,DRYAD,2018,https://datadryad.org
 inist.resif,78,Réseau sismologique et géodésique français,2014,https://www.resif.fr/
 inist.persyval,55,PERSYVAL-Lab : Pervasive Systems and Algorithms Lab,2016,

1-enrich-with-datacite/nb-dois.txt

-Mon Feb 19 17:31:57 UTC 2024
+2362
\ No newline at end of file

dois-uga.csv

@@ -6452,3 +6452,10 @@ models.",api,True,findable,0.0,0.0,0.0,1.0,0.0,2024-02-05T19:50:10.000Z,2024-02-
 This dataset contains all language data (in 2023, 25 language editions are supported) and contains one version per Wikimedia dump (one version twice a month).",api,True,findable,0.0,0.0,0.0,0.0,0.0,2024-01-09T15:40:33.000Z,2024-01-09T15:40:33.000Z,cern.zenodo,cern,"Wiktionary,LLOD,Linguistic Linked Open Data,Ontolex,RDF","[{'subject': 'Wiktionary'}, {'subject': 'LLOD'}, {'subject': 'Linguistic Linked Open Data'}, {'subject': 'Ontolex'}, {'subject': 'RDF'}]",,
 10.5281/zenodo.10548744,WRFChem MOSAiC run,Zenodo,2024.0,,Dataset,Creative Commons Attribution 4.0 International,WRFChem MOSAiC run - March 15 to April 30 2020. From https://doi.org/10.1525/elementa.2022.00129,api,True,findable,0.0,0.0,0.0,0.0,0.0,2024-01-22T11:19:08.000Z,2024-01-22T11:19:08.000Z,cern.zenodo,cern,,,,
 10.6084/m9.figshare.12926231,Additional file 1 of Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit,figshare,2020.0,,Text,Creative Commons Attribution 4.0 International,Additional file 1. Pediatrics R1 Chlorhexidine-alcohol disinfection. Pediatrics R2 and R4 US and site of insertion. Pediatrics R3 radial vs. femoral artery access. Pediatrics R5 impregnated impregnated CVCs. Pediadrics R6 heparin bonded CVCs. Pediatrics R7 continuous quality improvement program. Pediatrics R8 CHG dressings CVCs and arterial catheters. Adults and pediatrics Prevention R 1-1 and 1-2 subclavian vs. Internal jugular vs. femoral. R 1-3 alc-CHG vs. alc-PVI. R 1-4 1 step vs. 4 steps desinfections. R 1-5 antiseptic and antibiotic impregnated catheters. R1-6 heparin bonded CVCs. R 1-7 CHG dressings vs. transparent dressings. R 1-8 dressing change frequencies. R 1-9 R1-10 R 1-11 R1-12 US and site of insertion. Surveillance R 2.1 R2.2 surveillance network. R 2-2 quality improvement program. R2-3 culture of catheters Catheter related infection R3-1 R3-4 blood culture. R3-2 R3-3a R3-3b persistent bacteraemia : R 3-5 R3-6 R3-7 R3-9 R3-15 Catheter removed. R3-8 R3-10 R3-12 R3-13 duration of antibiotics. R3-11 antifungal therapy R3-14 antibiotic therapy.,mds,True,findable,0.0,0.0,2.0,1.0,0.0,2020-09-08T03:48:23.000Z,2020-09-08T03:48:24.000Z,figshare.ars,otjm,"Medicine,Cell Biology,Environmental Sciences not elsewhere classified,Biological Sciences not elsewhere classified,Marine Biology,Science Policy,Infectious Diseases,FOS: Health sciences","[{'subject': 'Medicine'}, {'subject': 'Cell Biology'}, {'subject': 'Environmental Sciences not elsewhere classified'}, {'subject': 'Biological Sciences not elsewhere classified'}, {'subject': 'Marine Biology'}, {'subject': 'Science Policy'}, {'subject': 'Infectious Diseases'}, {'subject': 'FOS: Health sciences', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}]",['427118 Bytes'],
+10.6084/m9.figshare.12421352,Additional file 1 of Impact of take-home messages written into slide presentations delivered during lectures on the retention of messages and the residents’ knowledge: a randomized controlled study,figshare,2020.0,,Text,Creative Commons Attribution 4.0 International,Additional file 1. List of lectures.,mds,True,findable,0.0,0.0,18.0,0.0,0.0,2020-06-04T03:57:16.000Z,2020-06-04T03:57:17.000Z,figshare.ars,otjm,"Medicine,Sociology,FOS: Sociology,Immunology,FOS: Clinical medicine,Biological Sciences not elsewhere classified,Cancer,Science Policy","[{'subject': 'Medicine'}, {'subject': 'Sociology'}, {'subject': 'FOS: Sociology', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}, {'subject': 'Immunology'}, {'subject': 'FOS: Clinical medicine', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}, {'subject': 'Biological Sciences not elsewhere classified'}, {'subject': 'Cancer'}, {'subject': 'Science Policy'}]",['13820 Bytes'],
+10.6084/m9.figshare.c.7081935,Healthcare-associated infections in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study,figshare,2024.0,,Collection,Creative Commons Attribution 4.0 International,"Abstract Background Both critically ill patients with coronavirus disease 2019 (COVID-19) and patients receiving extracorporeal membrane oxygenation (ECMO) support exhibit a high incidence of healthcare-associated infections (HAI). However, data on incidence, microbiology, resistance patterns, and the impact of HAI on outcomes in patients receiving ECMO for severe COVID-19 remain limited. We aimed to report HAI incidence and microbiology in patients receiving ECMO for severe COVID-19 and to evaluate the impact of ECMO-associated infections (ECMO-AI) on in-hospital mortality. Methods For this study, we analyzed data from 701 patients included in the ECMOSARS registry which included COVID-19 patients supported by ECMO in France. Results Among 602 analyzed patients for whom HAI and hospital mortality data were available, 214 (36%) had ECMO-AI, resulting in an incidence rate of 27 ECMO-AI per 1000 ECMO days at risk. Of these, 154 patients had bloodstream infection (BSI) and 117 patients had ventilator-associated pneumonia (VAP). The responsible microorganisms were Enterobacteriaceae (34% for BSI and 48% for VAP), Enterococcus species (25% and 6%, respectively) and non-fermenting Gram-negative bacilli (13% and 20%, respectively). Fungal infections were also observed (10% for BSI and 3% for VAP), as were multidrug-resistant organisms (21% and 15%, respectively). Using a Cox multistate model, ECMO-AI were not found associated with hospital death (HR = 1.00 95% CI [0.79–1.26], p = 0.986). Conclusions In a nationwide cohort of COVID-19 patients receiving ECMO support, we observed a high incidence of ECMO-AI. ECMO-AI were not found associated with hospital death. Trial registration number NCT04397588 (May 21, 2020).",mds,True,findable,0.0,0.0,0.0,0.0,0.0,2024-02-20T04:42:20.000Z,2024-02-20T04:42:21.000Z,figshare.ars,otjm,"Microbiology,FOS: Biological sciences,Immunology,FOS: Clinical medicine,Cancer,Science Policy,Infectious Diseases,FOS: Health sciences,Virology","[{'subject': 'Microbiology'}, {'subject': 'FOS: Biological sciences', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}, {'subject': 'Immunology'}, {'subject': 'FOS: Clinical medicine', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}, {'subject': 'Cancer'}, {'subject': 'Science Policy'}, {'subject': 'Infectious Diseases'}, {'subject': 'FOS: Health sciences', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}, {'subject': 'Virology'}]",,
+10.6084/m9.figshare.15033205,Additional file 2 of Variability of multi-omics profiles in a population-based child cohort,figshare,2021.0,,Dataset,Creative Commons Attribution 4.0 International,"Additional file 2. Results of the variance explained by each explanatory variable in each omics feature. This file contains, for each omics layer (one per sheet), the percentage of variance explained by each explanatory variable in each omics feature.",mds,True,findable,0.0,0.0,54.0,1.0,0.0,2021-07-22T03:31:45.000Z,2021-07-22T03:31:47.000Z,figshare.ars,otjm,"Genetics,FOS: Biological sciences","[{'subject': 'Genetics'}, {'subject': 'FOS: Biological sciences', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}]",['23779562 Bytes'],
+10.6084/m9.figshare.25248759,Additional file 1 of Healthcare-associated infections in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study,figshare,2024.0,,Text,Creative Commons Attribution 4.0 International,Additional file 1 of Healthcare-associated infections in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study.,mds,True,findable,0.0,0.0,29.0,0.0,0.0,2024-02-20T04:42:19.000Z,2024-02-20T04:42:19.000Z,figshare.ars,otjm,"Microbiology,FOS: Biological sciences,Immunology,FOS: Clinical medicine,Cancer,Science Policy,Infectious Diseases,FOS: Health sciences,Virology","[{'subject': 'Microbiology'}, {'subject': 'FOS: Biological sciences', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}, {'subject': 'Immunology'}, {'subject': 'FOS: Clinical medicine', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}, {'subject': 'Cancer'}, {'subject': 'Science Policy'}, {'subject': 'Infectious Diseases'}, {'subject': 'FOS: Health sciences', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}, {'subject': 'Virology'}]",['93615 Bytes'],
+10.6084/m9.figshare.15033202,Additional file 1 of Variability of multi-omics profiles in a population-based child cohort,figshare,2021.0,,Text,Creative Commons Attribution 4.0 International,"Additional file 1. Supplementary tables, figures and R code. This file contains supplementary methods, tables and figures summarizing the results of the variance partition models. It also contains the code used in R to perform variance partition analyses and Gaussian graphical models.",mds,True,findable,0.0,0.0,54.0,1.0,0.0,2021-07-22T03:31:44.000Z,2021-07-22T03:31:45.000Z,figshare.ars,otjm,"Genetics,FOS: Biological sciences","[{'subject': 'Genetics'}, {'subject': 'FOS: Biological sciences', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}]",['413915 Bytes'],
+10.5281/zenodo.10680534,NeoGeographyToolkit/StereoPipeline: 2024-02-19-daily-build,Zenodo,2024.0,,Software,Creative Commons Attribution 4.0 International,Recent additions log: https://stereopipeline.readthedocs.io/en/latest/news.html,api,True,findable,0.0,0.0,0.0,1.0,0.0,2024-02-19T17:20:19.000Z,2024-02-19T17:20:19.000Z,cern.zenodo,cern,,,,
+10.6084/m9.figshare.12421358,Additional file 2 of Impact of take-home messages written into slide presentations delivered during lectures on the retention of messages and the residents’ knowledge: a randomized controlled study,figshare,2020.0,,Text,Creative Commons Attribution 4.0 International,Additional file 2. Examples of Multiple Choice Questions.,mds,True,findable,0.0,0.0,18.0,0.0,0.0,2020-06-04T03:57:26.000Z,2020-06-04T03:57:27.000Z,figshare.ars,otjm,"Medicine,Sociology,FOS: Sociology,Immunology,FOS: Clinical medicine,Biological Sciences not elsewhere classified,Cancer,Science Policy","[{'subject': 'Medicine'}, {'subject': 'Sociology'}, {'subject': 'FOS: Sociology', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}, {'subject': 'Immunology'}, {'subject': 'FOS: Clinical medicine', 'schemeUri': 'http://www.oecd.org/science/inno/38235147.pdf', 'subjectScheme': 'Fields of Science and Technology (FOS)'}, {'subject': 'Biological Sciences not elsewhere classified'}, {'subject': 'Cancer'}, {'subject': 'Science Policy'}]",['12703 Bytes'],